These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 7767264)

  • 41. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Moskowitz CH; Nademanee A; Masszi T; Agura E; Holowiecki J; Abidi MH; Chen AI; Stiff P; Gianni AM; Carella A; Osmanov D; Bachanova V; Sweetenham J; Sureda A; Huebner D; Sievers EL; Chi A; Larsen EK; Hunder NN; Walewski J;
    Lancet; 2015 May; 385(9980):1853-62. PubMed ID: 25796459
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Autologous stem cell transplantation for Hodgkin's disease: busulfan, melphalan and thiotepa compared to a radiation-based regimen.
    Gutierrez-Delgado F; Holmberg L; Hooper H; Petersdorf S; Press O; Maziarz R; Maloney D; Chauncey T; Appelbaum F; Bensinger W
    Bone Marrow Transplant; 2003 Aug; 32(3):279-85. PubMed ID: 12858199
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Autologous stem cell transplantation for poor prognosis Hodgkin's disease in first complete remission: a retrospective study from the Spanish GEL-TAMO cooperative group.
    Sureda A; Mataix R; Hernández-Navarro F; Jarque I; Lahuerta JJ; Tomás JF; Brunet S; Caballero D; Conde E; León A; Fernández MN; López A; Maldonado J; Bengoechea E; Callís M; Carrera D; García-Conde J; García-Laraña J; Moraleda JM; Morey M; Rifón J; Sierra J; Torres A; Domingo-Albós A
    Bone Marrow Transplant; 1997 Aug; 20(4):283-8. PubMed ID: 9285542
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High-dose chemotherapy with autologous stem cell transplantation is an effective treatment of primary refractory Hodgkin's disease. Retrospective study of the Polish Lymphoma Research Group.
    Czyz J; Hellmann A; Dziadziuszko R; Hansz J; Goździk J; Hołowiecki J; Stella-Hołowiecka B; Kachel Ł; Knopińska-Posłuszny W; Nagler A; Meder J; Walewski J; Lampka E; Sułek K; Sawicki W; Lange A; Forgacz K; Suchnicki K; Pacuszko T; Skotnicki A; Mensah P; Jurczak W; Kuliczkowski K; Wróbel T; Mazur G; Dmoszyńska A; Wach M; Robak T; Warzocha K
    Bone Marrow Transplant; 2002 Jul; 30(1):29-34. PubMed ID: 12105774
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Treatment for Hodgkin's disease].
    Yokota A; Takagi T
    Nihon Rinsho; 2000 Mar; 58(3):677-81. PubMed ID: 10741146
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease.
    Jagannath S; Armitage JO; Dicke KA; Tucker SL; Velasquez WS; Smith K; Vaughan WP; Kessinger A; Horwitz LJ; Hagemeister FB
    J Clin Oncol; 1989 Feb; 7(2):179-85. PubMed ID: 2644397
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Protracted results of dose-intensive therapy using cyclophosphamide, carmustine, and continuous infusion etoposide with autologous stem cell support in patients with relapse or refractory Hodgkin's disease: a phase II study from the North American Marrow Transplant Group.
    Fleming DR; Wolff SN; Fay JW; Brown RA; Lynch JP; Bolwell BJ; Stevens DA; Goodman SA; Greer JP; Stein RS; Pineiro LA; Collins RH; Goldsmith LJ; Herzig GP; Herzig RH
    Leuk Lymphoma; 1999 Sep; 35(1-2):91-8. PubMed ID: 10512166
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Twelve years experience with high-dose therapy and autologous stem cell transplantation for high-risk Hodgkin's disease patients in first remission after MOPP/ABVD chemotherapy.
    Carella AM; Prencipe E; Pungolino E; Lerma E; Frassoni F; Rossi E; Giordano D; Occhini D; Gatti AM; Bruni R; Spriano M; Nati S; Pierluigi D; Congiu M; Vimercati R; Ravetti JL; Federico M
    Leuk Lymphoma; 1996 Mar; 21(1-2):63-70. PubMed ID: 8907271
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognosis of high dose chemotherapy/autologous bone marrow transplantation candidates not receiving this treatment after failure of primary therapy of Hodgkin's disease.
    Fuchs R; Löffler M; Pfreundschuh M; Dölken G; Gerhartz H; Hagen-Aukamp U; Hiller E; Petsch S; Pflüger KH; Rühl U
    Leuk Lymphoma; 1994 Jun; 14(1-2):79-89. PubMed ID: 7522721
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation.
    Stewart DA; Guo D; Glück S; Morris D; Chaudhry A; deMetz C; Klassen J; Brown CB; Russell JA
    Bone Marrow Transplant; 2000 Aug; 26(4):383-8. PubMed ID: 10982284
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation.
    Fernández-Jiménez MC; Canales MA; Ojeda E; de Bustos JG; Aguado MJ; Hernández-Navarro F
    Haematologica; 1999 Nov; 84(11):1007-11. PubMed ID: 10553161
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.
    Carella AM; Cavaliere M; Lerma E; Ferrara R; Tedeschi L; Romanelli A; Vinci M; Pinotti G; Lambelet P; Loni C; Verdiani S; De Stefano F; Valbonesi M; Corsetti MT
    J Clin Oncol; 2000 Dec; 18(23):3918-24. PubMed ID: 11099321
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant.
    Crump M; Smith AM; Brandwein J; Couture F; Sherret H; Sutton DM; Scott JG; McCrae J; Murray C; Pantalony D
    J Clin Oncol; 1993 Apr; 11(4):704-11. PubMed ID: 8478664
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High-dose ifosfamide and mitoxantrone (HDIM) in patients with relapsed or refractory Hodgkin's lymphoma.
    Aurer I; Nemet D; Mitrović Z; Dujmović D; Bašić-Kinda S; Radman I; Sertić D; Šantek F; Kralik M; Dotlić S; Mazić S; Labar B
    Ann Hematol; 2016 Jun; 95(7):1129-36. PubMed ID: 27103009
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High-dose chemotherapy and auto-SCT for relapsed and refractory Hodgkin's lymphoma patients refractory to first-line salvage chemotherapy but responsive to second-line salvage chemotherapy.
    Rauf MS; Maghfoor I; Elhassan TA; Akhtar S
    Med Oncol; 2015 Jan; 32(1):388. PubMed ID: 25429839
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [High dose chemoradiotherapy with autologous hemotopoietic stem cell transplantation for treatment of patients with advanced Hodgkin's lymphoma: a report of 11 cases].
    Zhou SY; Shi YK; He XH; Han XH; Liu P; Yang JL; Zhou AP; Feng FY
    Ai Zheng; 2002 Apr; 21(4):405-8. PubMed ID: 12452021
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Yttrium 90-labeled antiferritin followed by high-dose chemotherapy and autologous bone marrow transplantation for poor-prognosis Hodgkin's disease.
    Bierman PJ; Vose JM; Leichner PK; Quadri SM; Armitage JO; Klein JL; Abrams RA; Dicke KA; Vriesendorp HM
    J Clin Oncol; 1993 Apr; 11(4):698-703. PubMed ID: 8478663
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group.
    Sibon D; Morschhauser F; Resche-Rigon M; Ghez D; Dupuis J; Marçais A; Deau-Fischer B; Bouabdallah R; Sebban C; Salles G; Brice P
    Haematologica; 2016 Apr; 101(4):474-81. PubMed ID: 26721893
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Role of autologous stem cell transplantation in the treatment of Hodgkin's lymphoma].
    Barillari G; Fanin R; Biffoni F
    Recenti Prog Med; 1998 Feb; 89(2):87-98. PubMed ID: 9558912
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.
    Dawson LA; Saito NG; Ratanatharathorn V; Uberti JP; Adams PT; Ayash LJ; Reynolds CM; Silver SM; Schipper MJ; Lichter AS; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):208-18. PubMed ID: 15093918
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.